Wed, Apr 16, 2014, 1:28 AM EDT - U.S. Markets open in 8 hrs 2 mins

Recent

% | $
Quotes you view appear here for quick access.

Jazz Pharmaceuticals Public Limited Company Message Board

  • solo77796 solo77796 Sep 17, 2012 11:34 AM Flag

    Markman news

    Can anyone substantiate this: JAZZ up on favorable Markman ruling, patent suit vs Roxanne Labs

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Shorts are hanging on a narrow cliff.

      The bad news on Markman disappeared so what ever dream they have of additional bad news is fantasy.

      The buyers who have been awaiting this ruling are climbing on and will continue buying as we march forward.

      Sentiment: Strong Buy

      • 1 Reply to solo77796
      • Volume continues to be above avg. With stock moving higher and new short positions replacing our old JAZZ shorts, JAZZ remains at a fair market price. I predict the stock will be in the 70's before next earnings are announced and I anticipate short covering into the high 70's to low 80's.

        I am both happy and amused at the volume of repetitive unprofessional posters I see on this board showing just how nervous and frightened they are as we begin the next 30 point rise.

        3 cheers for all the investors who can look forward to holding JAZZ for another 3 years. I predict within 36 months JAZZ will initiate a cash dividend program. This will come about after several stock splits.

        Sentiment: Strong Buy

    • Jazz Pharmaceuticals Gains on Xyrem Court Ruling
      12:41p ET September 17, 2012 (Dow Jones) Jazz Pharmaceuticals Gains on Xyrem Court Ruling

      Shares of Jazz Pharmaceuticals PLC (JAZZ) jumped 13.2% to $54.47 recently following news that a federal court has issued a Markman ruling largely in favor of Jazz on its narcolepsy medication Xyrem.
      "The judge in the Xyrem patent case just issued the long awaited Markman ruling that defines the patent claim terms," wrote Jefferies analyst Corey Davis in his note Monday.
      "In our initial read, we count 17 occurrences of agreeing with the Jazz construction and zero occurrences of agreement with Roxane [Laboratories]. We have not had a chance to fully review the 43 page ruling, but at first blush this seems like a clear win for Jazz," Davis added.
      Jazz's stock has climbed approximately 12% over the past 30 days and over 41% year-to-date.

      • 1 Reply to minxmrphd
      • So does the stock remain bullish as we move forward. Does the stock end higher by Tuesdays close?

        It clearly looks to be breaking out and should begin to get above a fair market multiple on forward earnings, perhaps 20x on current earnings = $90+

        or speculating buyers are at ease over this ruling and perhaps it will become a buyout play?

        Clearly the outlook is guiding PMs above $100 over the next 12 months.

        Lets all be surprised as we end this quarter in two weeks and look for the earnings report prior to Election week..

 
JAZZ
130.91+2.66(+2.07%)Apr 15 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.